)
)
IN8bio Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from IN8bio Inc
Access all reports
IN8bio Inc., previously known as Incysus Therapeutics, is a clinical-stage biopharmaceutical company focused on the development of innovative gamma-delta T cell therapies for cancer treatment. Their portfolio includes lead product candidates in various phases of clinical trials, targeting conditions such as glioblastoma and acute leukemia, alongside a broad spectrum of preclinical programs aimed at solid tumors. Utilizing their proprietary DeltEx platform, IN8bio develops both autologous and allogeneic gamma-delta T cell therapies, leveraging the unique properties of gamma-delta T cells to differentiate between healthy and diseased tissues. The company was established in 2016 and is headquartered in New York, New York, with its primary scientific operations based in Birmingham, Alabama. Its shares are listed on the NASDAQ.
Latest articles
)
Under the Hood: AutoZone's Blueprint for Retail Excellence
An in-depth look at the largest aftermarket auto parts retailer in the U.S., its philosophy, and masterful capital allocation.
19 Dec 2024
)
Lessons from Gautam Baid: Mastering Simplicity and Compounding
Gautam Baid's journey of compounding wisdom, investing simplicity, and lifelong learning – insights to transform your financial and personal growth.
13 Dec 2024
)
Rocket Lab: Breaking Ground in Space
Rocket Lab has been one of the pioneers in the commercial aerospace industry, with numerous satellite launches and space system applications.
9 Dec 2024
Ticker symbol
INAB
Country
🇺🇸 United States